Current Drug Delivery, published by Bentham Science Publishers Ltd, serves as a vital platform for advancing the field of pharmaceutical sciences. With an ISSN of 1567-2018 and an E-ISSN of 1875-5704, this esteemed journal focuses on all aspects of drug delivery systems, encompassing innovative research and developments that aim to improve therapeutics and patient outcomes. Operating from the United Arab Emirates, it has an impressive standing reflected in its 2023 Q2 ranking in Pharmaceutical Sciences and a notable position within the 62nd percentile in Scopus’s Pharmacology, Toxicology, and Pharmaceutics category. The journal not only acts as an essential resource for researchers and professionals but it also encourages the dissemination of knowledge among students and budding scientists. With the latest articles and reviews converging from 2004 to 2024, Current Drug Delivery remains committed to offering high-quality content that enhances understanding and sparks innovation in drug delivery mechanisms.

Nanomedicine, published by Future Medicine Ltd, is a premier academic journal dedicated to the rapidly evolving field of nanotechnology in medicine. With an emphasis on innovative research and applications, this journal encompasses a broad spectrum of topics including bioengineering, biomedical engineering, and nanoscience, among others. Featuring an impressive Q1 ranking in Development and multiple Q2 rankings across significant categories, it serves as a pivotal resource for researchers and professionals aiming to stay at the forefront of advancements in these disciplines. While the journal is not open access, it is accessible through various institutional subscriptions, ensuring wide dissemination of cutting-edge findings. Notably, it has achieved substantial impact within the scientific community, indicated by its high rankings in Scopus and overall commitment to enhancing the understanding and application of nanomedicine. This journal is a vital conduit for fostering collaborations and innovations that transcend traditional medical paradigms.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.

International Journal of Pharmaceutics-X is a premier open access journal published by Elsevier, dedicated to advancing knowledge and research in the field of pharmaceutical sciences. Launched in 2019, this journal has quickly ascended to the Q1 category in the 2023 Category Quartiles, reflecting its high impact and the quality of research it promotes. With a current Scopus ranking of #49 out of 183 in the Pharmacology, Toxicology and Pharmaceutics category, this journal occupies the 73rd percentile, showcasing its significant influence within the scholarly community. Emphasizing innovative research and novel applications, the International Journal of Pharmaceutics-X offers a platform for researchers, professionals, and students to disseminate their findings, making crucial contributions to the global pharmaceutical landscape. The journal is based in the Netherlands, presenting a vibrant hub for scientific discourse and collaboration in a rapidly evolving field.

Drug Delivery and Translational Research (ISSN: 2190-393X | E-ISSN: 2190-3948), published by Springer Heidelberg, stands at the forefront of the Pharmaceutical Sciences discipline, boasting a prestigious impact factor as evidenced by its Q1 category ranking in 2023. This esteemed journal is dedicated to the vital intersection of drug delivery systems and translational research, aiming to bridge the gap between laboratory findings and clinical applications. It features groundbreaking studies that enhance our understanding of drug pharmacokinetics, formulations, and patient-centered research, making it indispensable for researchers, professionals, and students striving to innovate and excel in the field. While the journal operates under a subscription model, its commitment to disseminating high-quality research is reflected in its Scopus rank, placing it in the top 6% of its category (Rank #11/183, 94th percentile). Since its inception in 2011, it has garnered significant attention, promoting advances in pharmacology, toxicology, and pharmaceutics, and continues to be a platform for vital discourse and discovery.

PHARMACEUTICAL RESEARCH, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the ever-evolving field of pharmaceutical sciences. With an ISSN of 0724-8741 and an E-ISSN of 1573-904X, this journal has established itself as a critical hub for disseminating innovative research from 1984 to 2024. The journal holds impressive rankings in prominent categories, including Q2 in Biotechnology and Q2 in Pharmaceutical Science, reflecting its robust impact on the global scientific community. The journal aims to provide researchers, professionals, and students with high-quality articles that contribute significantly to the advancement of drug development and medicinal applications. Although it does not currently offer Open Access options, its rigorous peer-review process ensures that only the highest caliber research is published, making it a valuable resource for those seeking to stay at the forefront of pharmaceutical innovation.

The JOURNAL OF PHARMACEUTICAL SCIENCES, published by ELSEVIER SCIENCE INC, stands as a cornerstone in the field of pharmaceutical sciences, offering a platform for innovative research and advancements since its inception in 1961. With an impressive Scopus Rank of #36 out of 183 in the Pharmaceutical Science category, this journal is recognized for its commitment to disseminating high-quality, peer-reviewed studies that significantly contribute to the realms of pharmacology, toxicology, and pharmaceutics. Holding a 2023 Q2 category quartile, it attracts a diverse readership encompassing researchers, industry professionals, and students eager to advance their understanding and expertise. While the journal is not open access, it ensures valuable insights in every issue, making it an essential resource for those dedicated to the evolving landscape of pharmaceutical research. With an impact factor that reflects its relevance and influence, the JOURNAL OF PHARMACEUTICAL SCIENCES continues to shape the discourse in its domain, fostering innovation and collaboration among scholars worldwide.

The Future Journal of Pharmaceutical Sciences, published by Springer, stands as a vital resource in the realm of pharmaceutical research and innovation. Recognized for its open access initiative since 2015, this journal promotes extensive dissemination of cutting-edge discoveries, fostering collaboration among researchers, industry professionals, and students alike. With an ISSN of 2314-7245 and an E-ISSN of 2314-7253, it aims to bridge the gap between laboratory research and practical applications in the pharmaceutical sciences. Although specific metrics like HIndex and Scopus ranks are currently unavailable, the journal's commitment to high-quality, peer-reviewed content positions it as a promising platform for advancing pharmaceutical science. By engaging with this journal, contributors and readers can participate in the vibrant discourse shaping the future of drug development, therapeutic strategies, and healthcare solutions.

Therapeutic Delivery is a prestigious journal dedicated to advancing the field of Pharmaceutical Science, published by Newlands Press Ltd. Since its inception in 2010, this journal has become a vital resource for researchers and professionals alike, focusing on innovative drug delivery systems and therapeutic approaches that enhance patient care. With an impressive impact factor reflective of its credibility and scholarly influence, Therapeutic Delivery is currently ranked in the Q2 quartile and placed at Rank #64 out of 183 in the realm of Pharmacology, Toxicology, and Pharmaceutics, showcasing its prominence in the field. The journal operates with an Open Access format, ensuring that groundbreaking research is readily available to a global audience. Based in the United Kingdom, it publishes comprehensive articles that cover a wide spectrum of topics within pharmaceutical sciences, from molecular mechanisms to clinical applications, thus catering to both academic and professional readerships. Researchers, students, and industry professionals will find Therapeutic Delivery an invaluable platform for sharing insights and fostering advancements in therapeutic methodologies.

Expert Opinion on Drug Delivery is a leading journal in the field of pharmaceutical science, published by Taylor & Francis Ltd. With an impressive impact factor and a prestigious Q1 ranking in 2023, it stands out as a vital resource for researchers, professionals, and students dedicated to advancing drug delivery technologies. Established in 2004, the journal has consistently provided a platform for critical insights and expert analyses, bridging the gap between innovation and application in drug delivery systems. Although it currently does not offer Open Access options, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to the fields of pharmacology, toxicology, and pharmaceutics. With its robust ranking of 13th out of 183 in Scopus, the journal continues to foster discourse and collaboration among experts, thereby enhancing the advancement of therapeutic options and improving patient outcomes.